Anticoagulation Management

Introduction to Reversal Strategies

• The American College of Cardiology recommends administering oral vitamin K1 (1.0-2.5 mg) for patients with high bleeding risk, with oral administration preferred for non-urgent INR reversal due to predictable effectiveness, convenience, and safety compared to parenteral routes 1
• The American College of Cardiology and the American Heart Association support the use of 4-factor prothrombin complex concentrate (PCC) at a dose of 25-50 units/kg based on INR and weight to rapidly reverse anticoagulation, with low-dose vitamin K 1-2.5 mg orally or IV to prevent potential bleeding complications 2, 1, 3, 4

Administration Routes and Dosages

• Intravenous administration of vitamin K1 should be reserved for cases requiring very rapid reversal, given by slow infusion (over 30 minutes), and carries a risk of anaphylactic reactions, as recommended by the American College of Cardiology 1
• Subcutaneous administration is not recommended due to unpredictable and sometimes delayed response, as stated by the American College of Cardiology 1
• High-dose vitamin K (>5 mg) should be avoided to prevent hypercoagulability, as recommended by the American Heart Association 2

Monitoring and Dosing Considerations

• INR should be checked within 24 hours after vitamin K administration, as advised by the American College of Cardiology 1
• High doses of vitamin K1 (>10 mg) may cause warfarin resistance for up to a week, while low doses (1-2.5 mg) effectively reduce INR without causing significant warfarin resistance, as noted by the American College of Cardiology 1
• INR falls over several days after warfarin interruption without vitamin K, with an INR between 2.0-3.0 falling to normal range in 4-5 days, as stated by the American College of Cardiology 1

Reversal Outcomes and Considerations

• PCC is preferred over fresh frozen plasma (FFP) for rapid INR reversal due to its faster onset of action, lower volume requirement, more complete reversal of anticoagulation, and lower risk of transfusion reactions, as stated by the American Society of Hematology and the American College of Cardiology 2, 1, 3, 4
• The following table summarizes the recommended management strategies for elevated INR:

• Patients with mechanical heart valves should avoid rapid reversal unless there is potentially life-threatening bleeding, as recommended by the European Heart Journal and the Stroke journal 5, 6

Patient-Specific Considerations

• Advanced age, renal insufficiency, and liver disease are factors to consider in INR management, as suggested by the American Geriatrics Society and the European Heart Journal 7, 5
• Concomitant use of non-steroidal anti-inflammatory drugs and nutritional deficiency with reduced protein levels are factors to consider in INR management, as noted by the American Geriatrics Society 7, 8
• Cancer-related coagulopathy can cause direct activation of coagulation pathways, liver dysfunction affecting clotting factor synthesis, and nutritional deficiencies affecting vitamin K status, as noted by the American College of Physicians 2

Management of Elevated INR

• For patients with INR 3.0-5.0, omitting a dose of warfarin or reducing the dose is recommended, with resumption when INR is within therapeutic range, and no vitamin K is required, as suggested by the American Geriatrics Society 7
• For patients with INR 5.0-9.0, temporary suspension of warfarin, daily INR monitoring, and administration of oral vitamin K1 (1.0-2.5 mg) for those with high bleeding risk is recommended, as suggested by the American College of Cardiology and the American Geriatrics Society 1, 8
• For patients with INR >9.0, suspending warfarin, administering oral vitamin K1 (2.5-5.0 mg), and monitoring INR every 24 hours, with consideration of additional vitamin K1 dose (1.0-2.0 mg) if INR remains elevated after 24 hours is recommended, as suggested by the American College of Cardiology 1, 8

Special Considerations

• Prophylactic platelet transfusion is recommended before central line placement if platelet count is <50,000/mm³ in patients with thrombocytopenia, as suggested by the American Academy of Otolaryngology-Head and Neck Surgery 9
• Consultation with the primary team managing anticoagulation is recommended before reversal in patients on anticoagulation for mechanical heart valves or other high-risk conditions, as recommended by the American Academy of Otolaryngology-Head and Neck Surgery and the American Heart Association 10, 6